Amgen (AMGN) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

AMGN Stock Forecast

Amgen stock forecast is as follows: an average price target of $301.81 (represents a 4.11% upside from AMGN’s last price of $289.90) and a rating consensus of 'Buy', based on 25 wall street analysts offering a 1-year stock forecast.

AMGN Price Target

The average price target for Amgen (AMGN) is $301.81 based on 1-year price targets from 25 Wall Street analysts in the past 3 months, with a price target range of $405.00 to $182.00. This represents a potential 4.11% upside from AMGN's last price of $289.90.

AMGN Analyst Ratings

Buy

According to 25 Wall Street analysts, Amgen's rating consensus is 'Buy'. The analyst rating breakdown for AMGN stock is 0 'Strong Buy' (0.00%), 15 'Buy' (60.00%), 8 'Hold' (32.00%), 2 'Sell' (8.00%), and 0 'Strong Sell' (0.00%).

Amgen Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 12, 2024	Michael Yee	Jefferies	-	-	27.16%	31.08%
Nov 12, 2024	Olivia Brayer	Cantor Fitzgerald	-	-	35.52%	39.70%
Oct 21, 2024	Terence Flynn	Morgan Stanley	-	-	0.71%	10.04%
Oct 16, 2024	Salveen Richter	Goldman Sachs	-	-	13.51%	27.29%
Oct 07, 2024	Carter Gould	Barclays	-	-	-1.46%	8.66%
Sep 25, 2024	Evan David Seigerman	BMO Capital	-	-	9.39%	24.87%
Sep 25, 2024	Christopher Raymond	Raymond James	-	-	3.95%	18.66%
Sep 25, 2024	Brian Skorney	Robert W. Baird	-	-	-35.03%	-25.84%
Aug 07, 2024	Mohit Bansal	Wells Fargo	-	-	1.84%	15.56%
Aug 06, 2024	Terence Flynn	Morgan Stanley	-	-	-8.40%	4.52%

Row per page

Go to

The latest Amgen stock forecast, released on Nov 12, 2024 by Michael Yee from Jefferies, set a price target of $380.00, which represents a 27.16% increase from the stock price at the time of the forecast ($298.84), and a 31.08% increase from AMGN last price ($289.90).

Amgen Price Target by Period

	1M	3M	12M
# Anlaysts	2	8	18
Avg Price Target	$392.50	$338.63	$327.00
Last Closing Price	$289.90	$289.90	$289.90
Upside/Downside	35.39%	16.81%	12.80%

In the current month, the average price target of Amgen stock is $392.50, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 35.39% increase as opposed to Amgen's last price of $289.90. This month's average price target is up 15.91% compared to last quarter, and up 20.03% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 13, 2024	Citigroup		Neutral	Initialise
Nov 12, 2024	Barclays	Negative	Negative	Hold
Nov 12, 2024	Cantor Fitzgerald	Overweight	Overweight	Hold
Oct 22, 2024	Wells Fargo	Buy	Buy	Hold
Oct 21, 2024	Morgan Stanley	Equal-Weight	Equal-Weight	Hold
Oct 21, 2024	Cowen & Co.	Buy	Buy	Hold
Oct 17, 2024	Bernstein		Outperform	Initialise
Oct 16, 2024	Goldman Sachs	Conviction Buy	Conviction Buy	Hold
Oct 07, 2024	Barclays	Equal-Weight	Equal-Weight	Hold
Sep 27, 2024	Cantor Fitzgerald		Overweight	Initialise

Row per page

Go to

Amgen's last stock rating was published by Citigroup on Nov 13, 2024. The company Initialise its AMGN rating from "null" to "Neutral".

Amgen Financial Forecast

Amgen Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$8.20B	$6.90B	$6.99B	$6.11B	$6.84B	$6.65B	$6.59B	$6.24B	$6.85B	$6.71B	$6.53B	$5.90B	$6.63B	$6.42B	$6.21B	$6.16B	$6.20B	$5.74B
Avg Forecast	$8.70B	$8.47B	$8.47B	$7.91B	$8.96B	$8.67B	$8.69B	$8.09B	$8.85B	$8.50B	$8.35B	$7.45B	$8.13B	$6.93B	$6.66B	$6.15B	$6.74B	$6.56B	$6.53B	$6.07B	$6.87B	$6.67B	$6.46B	$6.26B	$6.57B	$6.39B	$6.19B	$6.00B	$6.03B	$5.63B
High Forecast	$9.06B	$8.82B	$8.82B	$8.23B	$9.33B	$9.03B	$9.05B	$8.44B	$9.13B	$8.50B	$8.35B	$7.45B	$8.30B	$8.33B	$6.94B	$6.41B	$7.02B	$6.56B	$6.53B	$6.07B	$6.87B	$6.67B	$6.46B	$6.26B	$6.57B	$6.39B	$6.19B	$6.00B	$6.03B	$5.63B
Low Forecast	$8.27B	$8.05B	$8.05B	$7.52B	$8.52B	$8.24B	$8.26B	$7.66B	$8.56B	$8.50B	$8.35B	$7.45B	$7.98B	$6.73B	$6.33B	$5.85B	$6.41B	$6.56B	$6.53B	$6.07B	$6.87B	$6.67B	$6.46B	$6.26B	$6.57B	$6.39B	$6.19B	$6.00B	$6.03B	$5.63B
# Analysts	4	4	4	4	3	3	3	5	16	8	9	9	10	18	15	9	10	16	8	10	9	9	13	9	9	10	10	10	9	9
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.01%	1.00%	1.05%	0.99%	1.01%	1.01%	1.01%	1.03%	1.00%	1.01%	1.01%	0.94%	1.01%	1.01%	1.00%	1.03%	1.03%	1.02%

Amgen's average Quarter revenue forecast for Mar 24 based on 9 analysts is $7.45B, with a low forecast of $7.45B, and a high forecast of $7.45B. AMGN's average Quarter revenue forecast represents a -9.08% decrease compared to the company's last Quarter revenue of $8.20B (Dec 23).

Amgen EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	16	8	9	9	10	18	15	9	10	16	8	10	9	9	13	9	9	10	10	10	9	9
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$1.27B	$2.02B	$2.68B	$3.98B	$2.16B	$2.76B	$1.86B	$1.97B	$3.32B	$3.30B	$3.20B	$2.98B	$3.07B	$3.41B	$3.26B	$3.26B	$2.99B	$3.10B
Avg Forecast	$4.22B	$4.11B	$4.11B	$3.84B	$4.35B	$4.21B	$4.22B	$3.92B	$4.29B	$4.12B	$4.05B	$3.28B	$3.94B	$3.36B	$3.23B	$2.98B	$3.46B	$2.67B	$2.66B	$2.71B	$2.80B	$2.71B	$2.63B	$3.24B	$2.68B	$2.60B	$2.52B	$2.91B	$2.45B	$2.29B
High Forecast	$4.39B	$4.28B	$4.28B	$3.99B	$4.53B	$4.38B	$4.39B	$4.09B	$4.43B	$4.12B	$4.05B	$3.93B	$4.02B	$4.04B	$3.37B	$3.57B	$4.15B	$2.67B	$2.66B	$3.25B	$2.80B	$2.71B	$2.63B	$3.89B	$2.68B	$2.60B	$2.52B	$3.49B	$2.45B	$2.29B
Low Forecast	$4.01B	$3.90B	$3.91B	$3.65B	$4.13B	$4.00B	$4.01B	$3.71B	$4.15B	$4.12B	$4.05B	$2.62B	$3.87B	$3.26B	$3.07B	$2.38B	$2.76B	$2.67B	$2.66B	$2.17B	$2.80B	$2.71B	$2.63B	$2.59B	$2.68B	$2.60B	$2.52B	$2.33B	$2.45B	$2.29B
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.32%	0.60%	0.83%	1.34%	0.63%	1.03%	0.70%	0.73%	1.19%	1.22%	1.22%	0.92%	1.15%	1.31%	1.29%	1.12%	1.22%	1.35%

9 analysts predict AMGN's average Quarter EBITDA for Mar 24 to be $3.28B, with a high of $3.93B and a low of $2.62B. This is 157.82% upper than Amgen's previous annual EBITDA (Dec 23) of $1.27B.

Amgen Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	16	8	9	9	10	18	15	9	10	16	8	10	9	9	13	9	9	10	10	10	9	9
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$767.00M	$1.73B	$1.38B	$2.84B	$1.62B	$2.14B	$1.32B	$1.48B	$1.90B	$1.88B	$464.00M	$1.65B	$1.61B	$2.02B	$1.80B	$1.82B	$1.70B	$1.97B
Avg Forecast	$2.15B	$3.07B	$2.87B	$2.63B	$2.91B	$2.93B	$2.90B	$2.54B	$2.74B	$2.86B	$2.70B	$1.72B	$2.49B	$2.53B	$2.44B	$1.56B	$1.98B	$2.42B	$2.40B	$1.42B	$2.18B	$2.32B	$2.21B	$1.79B	$1.82B	$2.12B	$2.07B	$1.63B	$1.84B	$1.91B
High Forecast	$2.27B	$3.24B	$3.02B	$2.78B	$3.06B	$3.09B	$3.06B	$2.78B	$2.95B	$2.90B	$2.70B	$2.06B	$2.72B	$2.67B	$2.57B	$1.88B	$2.37B	$2.42B	$2.40B	$1.71B	$2.18B	$2.32B	$2.21B	$2.15B	$1.82B	$2.12B	$2.07B	$1.95B	$1.84B	$1.91B
Low Forecast	$2.02B	$2.88B	$2.68B	$2.47B	$2.72B	$2.74B	$2.72B	$2.25B	$2.57B	$2.82B	$2.70B	$1.38B	$2.32B	$2.32B	$2.28B	$1.25B	$1.58B	$2.42B	$2.40B	$1.14B	$2.18B	$2.32B	$2.21B	$1.43B	$1.82B	$2.12B	$2.07B	$1.30B	$1.84B	$1.91B
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.31%	0.68%	0.57%	1.82%	0.82%	0.89%	0.55%	1.04%	0.87%	0.81%	0.21%	0.92%	0.89%	0.95%	0.87%	1.12%	0.92%	1.03%

Amgen's average Quarter net income forecast for Mar 24 is $1.72B, with a range of $1.38B to $2.06B. AMGN's average Quarter net income forecast represents a 124.33% increase compared to the company's last Quarter net income of $767.00M (Dec 23).

Amgen SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	16	8	9	9	10	18	15	9	10	16	8	10	9	9	13	9	9	10	10	10	9	9
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$2.27B	$1.35B	$1.29B	$1.26B	$1.57B	$1.29B	$1.33B	$1.23B	$1.43B	$1.30B	$1.38B	$1.25B	$1.77B	$1.35B	$1.29B	$1.32B	$1.51B	$1.22B
Avg Forecast	$1.87B	$1.82B	$1.83B	$1.70B	$1.93B	$1.87B	$1.87B	$1.74B	$1.91B	$1.83B	$1.80B	$1.43B	$1.75B	$1.49B	$1.44B	$1.30B	$1.48B	$1.41B	$1.41B	$1.18B	$1.48B	$1.44B	$1.39B	$1.36B	$1.42B	$1.38B	$1.33B	$1.17B	$1.30B	$1.21B
High Forecast	$1.95B	$1.90B	$1.90B	$1.77B	$2.01B	$1.95B	$1.95B	$1.82B	$1.97B	$1.83B	$1.80B	$1.72B	$1.79B	$1.79B	$1.50B	$1.56B	$1.78B	$1.41B	$1.41B	$1.42B	$1.48B	$1.44B	$1.39B	$1.63B	$1.42B	$1.38B	$1.33B	$1.41B	$1.30B	$1.21B
Low Forecast	$1.78B	$1.73B	$1.74B	$1.62B	$1.83B	$1.78B	$1.78B	$1.65B	$1.84B	$1.83B	$1.80B	$1.15B	$1.72B	$1.45B	$1.36B	$1.04B	$1.19B	$1.41B	$1.41B	$946.46M	$1.48B	$1.44B	$1.39B	$1.09B	$1.42B	$1.38B	$1.33B	$938.00M	$1.30B	$1.21B
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.30%	0.91%	0.90%	0.97%	1.06%	0.91%	0.94%	1.04%	0.96%	0.91%	0.99%	0.92%	1.25%	0.98%	0.97%	1.12%	1.16%	1.01%

Amgen's average Quarter SG&A projection for Mar 24 is $1.43B, based on 9 Wall Street analysts, with a range of $1.15B to $1.72B. The forecast indicates a -37.05% fall compared to AMGN last annual SG&A of $2.27B (Dec 23).

Amgen EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	16	8	9	9	10	18	15	9	10	16	8	10	9	9	13	9	9	10	10	10	9	9
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$1.43	$3.23	$2.58	$5.32	$3.02	$4.01	$2.46	$2.69	$3.38	$3.32	$0.81	$2.85	$2.78	$3.45	$3.07	$3.09	$2.87	$3.29
Avg Forecast	$3.97	$5.67	$5.29	$4.86	$5.36	$5.41	$5.36	$4.68	$5.05	$5.27	$4.98	$3.88	$4.59	$4.67	$4.49	$3.85	$4.10	$4.47	$4.43	$4.10	$4.04	$4.29	$4.09	$4.05	$3.36	$3.93	$3.82	$3.74	$3.41	$3.53
High Forecast	$4.19	$5.98	$5.58	$5.12	$5.65	$5.70	$5.65	$5.13	$5.44	$5.35	$4.99	$3.88	$5.02	$4.92	$4.73	$4.05	$4.32	$4.47	$4.43	$4.10	$4.04	$4.29	$4.09	$4.05	$3.36	$3.93	$3.82	$3.74	$3.41	$3.53
Low Forecast	$3.72	$5.31	$4.95	$4.55	$5.02	$5.06	$5.01	$4.14	$4.74	$5.20	$4.98	$3.88	$4.29	$4.29	$4.20	$3.60	$3.83	$4.47	$4.43	$4.10	$4.04	$4.29	$4.09	$4.05	$3.36	$3.93	$3.82	$3.74	$3.41	$3.53
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.31%	0.69%	0.57%	1.38%	0.74%	0.90%	0.55%	0.66%	0.84%	0.77%	0.20%	0.70%	0.83%	0.88%	0.80%	0.83%	0.84%	0.93%

According to 9 Wall Street analysts, Amgen's projected average Quarter EPS for Mar 24 is $3.88, with a low estimate of $3.88 and a high estimate of $3.88. This represents a 171.26% increase compared to AMGN previous annual EPS of $1.43 (Dec 23).

Amgen Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
PFE	Pfizer	-	-	78.11%	Hold
BIIB	Biogen	-	-	75.05%	Buy
MRK	Merck	-	-	29.07%	Buy
JNJ	Johnson & Johnson	-	-	15.20%	Buy
BMY	Bristol-Myers Squibb Company	-	-	12.48%	Hold
AMGN	Amgen	-	-	4.11%	Buy
LLY	Eli Lilly and Company	-	-	3.76%	Buy
ABBV	AbbVie	-	-	0.91%	Buy
GILD	Gilead Sciences	-	-	-8.90%	Buy

AMGN Forecast FAQ

Is Amgen a good buy?

Yes, according to 25 Wall Street analysts, Amgen (AMGN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 15 'Buy' recommendations, accounting for 60.00% of AMGN's total ratings.

What is AMGN's price target?

Amgen (AMGN) average price target is $301.81 with a range of $182 to $405, implying a 4.11% from its last price of $289.9. The data is based on 25 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Amgen stock go up soon?

According to Wall Street analysts' prediction for AMGN stock, the company can go up by 4.11% (from the last price of $289.9 to the average price target of $301.81), up by 39.70% based on the highest stock price target, and down by -37.22% based on the lowest stock price target.

Can Amgen stock reach $400?

AMGN's highest twelve months analyst stock price target of $405 supports the claim that Amgen can reach $400 in the near future.

What is Amgen's current price target trend?

2 Wall Street analysts forecast a $392.5 price target for Amgen (AMGN) this month, up 35.39% from its last price of $289.9. Compared to the last 3 and 12 months, the average price target increased by 16.81% and increased by 12.80%, respectively.

What are Amgen's analysts' financial forecasts?

Amgen's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $34.41B (high $35.85B, low $32.68B), average EBITDA is $16.69B (high $17.39B, low $15.85B), average net income is $11.28B (high $11.99B, low $10.43B), average SG&A $7.42B (high $7.72B, low $7.04B), and average EPS is $20.82 (high $22.13, low $19.24). AMGN's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $33.55B (high $34.93B, low $31.88B), average EBITDA is $16.27B (high $16.94B, low $15.47B), average net income is $10.73B (high $11.31B, low $10.04B), average SG&A $7.23B (high $7.53B, low $6.87B), and average EPS is $19.8 (high $20.86, low $18.53).

Did the AMGN's actual financial results beat the analysts' financial forecasts?

Based on Amgen's last annual report (Dec 2023), the company's revenue was $28.19B, beating the average analysts forecast of $27.87B by 1.15%. Apple's EBITDA was $7.9B, missing the average prediction of $13.51B by -41.56%. The company's net income was $6.72B, missing the average estimation of $9.02B by -25.52%. Apple's SG&A was $6.18B, beating the average forecast of $5.98B by 3.32%. Lastly, the company's EPS was $12.56, missing the average prediction of $17.6 by -28.64%. In terms of the last quarterly report (Dec 2023), Amgen's revenue was $8.2B, beating the average analysts' forecast of $8.13B by 0.86%. The company's EBITDA was $1.27B, missing the average prediction of $3.94B by -67.76%. Amgen's net income was $767M, missing the average estimation of $2.49B by -69.18%. The company's SG&A was $2.27B, beating the average forecast of $1.75B by 29.88%. Lastly, the company's EPS was $1.43, missing the average prediction of $4.59 by -68.85%